Welcure Drugs&Pharma
Ticker > Company >

Welcure Drugs&Pharma share price

Welcure Drugs & Pharmaceuticals Ltd.

BSE: 524661 SECTOR: Trading  31.16 K   76   3

9.29
-0.48 (-4.91%)
BSE: 11 Sep 04:01 PM

Price Summary

Today's High

₹ 9.29

Today's Low

₹ 9.29

52 Week High

₹ 15.89

52 Week Low

₹ 6.4

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 104.38 Cr.

Enterprise Value

₹ 104.36 Cr.

No. of Shares

11.24 Cr.

P/E

3.72

P/B

0.82

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  11.39

CASH

₹ 0.02 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  2.5

Sales Growth

0%

ROE

-12.26 %

ROCE

-12.26%

Profit Growth

-271.57 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 Year-100%
5 Year-100%

Profit Growth

1 Year-271.57%
3 Year-246.95%
5 Year-314.23%

ROE%

1 Year-12.26%
3 Year9.82%
5 Year22.35%

ROCE %

1 Year-12.26%
3 Year9.85%
5 Year22.51%

Debt/Equity

0

Price to Cash Flow

-821.9

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 0.00 0.00
Mar 2025 0.00 0.00
Dec 2024 0.00 0.00
Sep 2024 0.00 0.00
Jun 2024 0.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of -246.950211260644% for the Past 3 years.
  • The company has shown a poor revenue growth of -100% for the Past 3 years.
  • Company has contingent liabilities of 0.33 Cr.
  • Company has negative cash flow from operations of -0.127.
  • Tax rate is low at 0.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0 24.55 8.84 21.21 299.92
Total Expenditure 0.34 22.71 7.92 20.58 268.77
Operating Profit -0.34 1.84 0.92 0.64 31.14
Other Income 0 0 0 1.91 0
Interest 0 0 0 0 0
Depreciation 0 0.01 0.01 0.01 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.35 1.84 0.91 2.54 31.14
Tax 0 0 0.5 0 7.84
Profit After Tax -0.35 1.84 0.42 2.54 23.3
Adjusted EPS (Rs) -0.26 0.16 0.04 0.23 2.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0.08 0.13 0.11 0 0
Total Expenditure 0.09 0.08 0.08 0.13 0.23
Operating Profit -0.01 0.06 0.02 -0.13 -0.23
Other Income 0 0 0 0.24 0.09
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.01 0.06 0.02 0.1 -0.18
Tax 0 0 0 0 0
Net Profit -0.01 0.06 0.02 0.1 -0.18
Adjusted EPS (Rs.) -0.01 0.05 0.02 0.08 -0.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.12 12.12 12.12 13.44 13.44
Total Reserves -12.1 -12.05 -12.03 -11.92 -12.1
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0.01 0 0 0.01 0.03
Total Liabilities 0.02 0.07 0.1 1.53 1.37
Assets
Net Block 0 0 0 0.06 0.02
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0.17 0
Loans & Advances 0 0 0.03 1.3 1.32
Other N/C Assets 0 0 0 0 0
Current Assets 0.02 0.07 0.07 0.01 0.03
Total Assets 0.02 0.07 0.1 1.53 1.37
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.01 0.06 0.02 0.1 -0.18
Adjustment 0 0 0 0 0.04
Changes in Assets & Liabilities 0 -0.01 -0.01 0.01 0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.01 0.04 0.02 0.11 -0.13
Investing Cash Flow 0 0 0 0 0.17
Financing Cash Flow 0 0 0 -0.17 -0.02
Net Cash Flow -0.01 0.04 0.02 -0.07 0.02

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
promoters 14.12 14.12 14.12 14.12 14.12
dharam chand jain 14.12 14.12 14.12 14.12 14.12
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 100.00 100.00 100.00 100.00 100.00
akshay nadiya - - 8.89 8.89 8.90
ankush rajkumar dabhane - - 8.89 8.89 5.53
avinashbhai govindbhai pa... - - 8.89 8.89 8.90
govindsingh bhavnathsingh... - - 8.00 8.00 8.01
jaydeep bhosle - - 8.00 8.00 8.01
kuldeep ranvirsingh tomar... - - 8.89 8.89 8.90
manish rajput - - 9.78 9.78 9.79
mitesh makvana - - 8.00 8.00 8.01
rahul ratansingh sikarwar... - - 9.78 9.78 9.79
tatad nayan gautambhai - - 8.89 8.89 8.90
manoj kumar kanda - 2.55 - - -
ruchira goyal - 7.49 - - -
shubham garg 1.93 1.93 - - -
sunil goel 1.58 1.58 - - -
vizwise commerce private ... 2.24 2.24 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Welcure Drugs&Pharma Stock Price Analysis and Quick Research Report. Is Welcure Drugs&Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Welcure Drugs&Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Welcure Drugs&Pharma has a PE ratio of 3.71540553511438 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Welcure Drugs&Pharma has ROA of -12.069% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Welcure Drugs&Pharma has a Current ratio of 1.0323.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Welcure Drugs&Pharma has a ROE of -12.2592%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Welcure Drugs&Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Welcure Drugs&Pharma has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Welcure Drugs&Pharma for the current financial year is 0%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Welcure Drugs&Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Welcure Drugs&Pharma is Rs 2.5004. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Welcure Drugs&Pharma in Ticker for free. Also, one can get the intrinsic value of Welcure Drugs&Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Welcure Drugs&Pharma FAQs

Q1. What is Welcure Drugs&Pharma share price today?
Ans: The current share price of Welcure Drugs&Pharma is Rs 9.29.

Q2. What is the market capitalisation of Welcure Drugs&Pharma?
Ans: Welcure Drugs&Pharma has a market capitalisation of Rs 104.380770587 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Welcure Drugs&Pharma?
Ans: The PE ratio of Welcure Drugs&Pharma is 3.71540553511438 and the P/B ratio of Welcure Drugs&Pharma is 0.815420130081015, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Welcure Drugs&Pharma share?
Ans: The 52-week high share price of Welcure Drugs&Pharma is Rs 15.89, and the 52-week low share price of Welcure Drugs&Pharma is Rs 6.4.

Q5. Does Welcure Drugs&Pharma pay dividends?
Ans: Currently, Welcure Drugs&Pharma does not pay dividends. Dividend yield of Welcure Drugs&Pharma is around 0%.

Q6. What are the face value and book value of Welcure Drugs&Pharma shares?
Ans: The face value of Welcure Drugs&Pharma shares is Rs 10, while the book value per share of Welcure Drugs&Pharma is around Rs 11.3929. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Welcure Drugs&Pharma?
Ans: Welcure Drugs&Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Welcure Drugs&Pharma?
Ans: The ROE of Welcure Drugs&Pharma is -12.2592% and ROCE of Welcure Drugs&Pharma is -12.2592%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Welcure Drugs&Pharma a good buy for the long term?
Ans: The Welcure Drugs&Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Welcure Drugs&Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Welcure Drugs&Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Welcure Drugs&Pharma’s financials?
Ans: You can review Welcure Drugs&Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Welcure Drugs&Pharma
X